WO2009140572A3 - Combinatorial treatment with glucose regulated protein-170 and melanoma differentiation associated gene-7 - Google Patents

Combinatorial treatment with glucose regulated protein-170 and melanoma differentiation associated gene-7 Download PDF

Info

Publication number
WO2009140572A3
WO2009140572A3 PCT/US2009/044092 US2009044092W WO2009140572A3 WO 2009140572 A3 WO2009140572 A3 WO 2009140572A3 US 2009044092 W US2009044092 W US 2009044092W WO 2009140572 A3 WO2009140572 A3 WO 2009140572A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated gene
regulated protein
melanoma differentiation
differentiation associated
glucose regulated
Prior art date
Application number
PCT/US2009/044092
Other languages
French (fr)
Other versions
WO2009140572A2 (en
Inventor
Paul B. Fisher
Xiang-Yang Wang
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of WO2009140572A2 publication Critical patent/WO2009140572A2/en
Publication of WO2009140572A3 publication Critical patent/WO2009140572A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods of treating cancer comprising administering, to a subject in need of such treatment, an effective amount of a combination of a GRP-170 and a MDA-7 molecule. The combined use of these agents allows effective therapy of cancers that may be relatively resistant to either agent alone.
PCT/US2009/044092 2008-05-15 2009-05-15 Combinatorial treatment with glucose regulated protein-170 and melanoma differentiation associated gene-7 WO2009140572A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5354808P 2008-05-15 2008-05-15
US61/053,548 2008-05-15

Publications (2)

Publication Number Publication Date
WO2009140572A2 WO2009140572A2 (en) 2009-11-19
WO2009140572A3 true WO2009140572A3 (en) 2010-03-04

Family

ID=41319356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044092 WO2009140572A2 (en) 2008-05-15 2009-05-15 Combinatorial treatment with glucose regulated protein-170 and melanoma differentiation associated gene-7

Country Status (1)

Country Link
WO (1) WO2009140572A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060269A2 (en) * 2002-12-23 2004-07-22 The Trustees Of Columbia University In The City Of New York Mda-7 and free radicals in the treatment of cancer
US20060292157A1 (en) * 2004-12-02 2006-12-28 The Trustees Of Columbia University In The City Of New York MDA-7 protein variants having antiproliferative activity
US20080103095A1 (en) * 1999-09-30 2008-05-01 Subjeck John R Stress protein compositions and methods for prevention and treatment of cancer and infectious disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103095A1 (en) * 1999-09-30 2008-05-01 Subjeck John R Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2004060269A2 (en) * 2002-12-23 2004-07-22 The Trustees Of Columbia University In The City Of New York Mda-7 and free radicals in the treatment of cancer
US20060292157A1 (en) * 2004-12-02 2006-12-28 The Trustees Of Columbia University In The City Of New York MDA-7 protein variants having antiproliferative activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN X. ET AL: "The 170 kDa glucose regulated stress protein is a large HSP70-, HSP110-like protein of the endoplasmic reticulum", FEBS LETTERS, vol. 380, 1996, pages 68 - 72, XP002060249 *
WANG ET AL.: "Extracellular Targeting of Endoplasmic Reticulum Chaperone Glucose-Regulated Protein 170 Enhances Tumor Immunity to a Poorly Immunogenic Melanoma.", THE JOURNAL OF IMMUNOLOGY, vol. 177, 2006, pages 1543 - 1551 *

Also Published As

Publication number Publication date
WO2009140572A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2012143499A3 (en) Novel binder-drug conjugates (adcs) and their use
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
WO2009064444A9 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
TN2011000200A1 (en) Combination therapy with peptide epoxyketones
EP2759302A3 (en) 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
PT2139483E (en) Combination therapies comprising a quinoxaline inhibitor of pi3k-alpha for use in the treatment of cancer
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2013061083A3 (en) Therapeutic agents and uses thereof
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
BRPI0908635B8 (en) compound and/or a pharmaceutically acceptable salt thereof and pharmaceutical composition
WO2008010991A3 (en) Methods and compositions for the treatment of cancer
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
WO2009138507A3 (en) Anti-cancer combination therapy
WO2010065563A3 (en) Apratoxin therapeutic agents: mechanism and methods of treatment
MX2010009697A (en) Improved anticancer treatments.
WO2008039525A3 (en) Cadherin antagonists in combination with anticancer agents for use in cancer treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09747653

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09747653

Country of ref document: EP

Kind code of ref document: A2